JAN 13 7003 P. JAN 14 7003 P. JAN 14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JAN 2 1 2003

TECH CENTER 1600/2900

In re Application of:

Confirmation No. 3677

Anderson et al.

Group: 1638

Examiner: Anne R. Kubelik

Serial No. 10/072,809

Filed: February 8, 2002

PLANT-DERIVED MOLECULES AND GENETIC SEQUENCES ENCODING SAME AND USES

THEREFOR

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express mail in an envelope addressed to Commissioner of Patents, Washington, D.C. 20231, No. EV 250 906

314 US on

Date / Kay Speak

STATEMENT UNDER 37 C.F.R. §1.821-824

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

For:

The above-identified patent application contains sequences as defined in 37 C.F.R. §1.821(a). Accordingly, the Specification includes a paper copy of Sequence Listing as pages 1-39. Applicants also submit a write-protected diskette copy of the Sequence Listing in computer-readable form as required by 37 C.F.R. §1.821(e) and a paper copy of the Sequence Listing, both prepared using PatentIn Release 3.0. The present submission includes no new matter.

In compliance with 37 C.F.R. §1.821(f), the undersigned states that the content of the paper copies and computer-readable copies of the Sequence Listing are the same.

Respectfully submitted,

Heeja Yoo-Warren Reg. No. 45,495

Greenlee, Winner and Sullivan, P.C. 5370 Manhattan Circle, Suite 201

Boulder, Colorado 80303 Phone: 303-499-8080 Fax: 303-499-8089

email: winner@greenwin.com

ks: 01/13/03

18-01

BEST AVAILABLE COPY

QIPE &		
JAN 1 3 2003 RS	Application No.	Applicant(s)
Notice to Comply	10/072,809 Examiner	ANDERSON ET AL. Art Unit
1100.00	Anne R. Kubelik	1638

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements

e.	The nucleotide and/or amino acid sequence disclosure contained in this application costs. for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):	
2	□ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).	
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).	
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).	
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be unbesited as required by 37 C.F.R. 1.825(d).	
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
	☑ 7. Other: Sequence identifiers are missing as indicated on the accompanying letter.	
	Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the	۵
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
	For questions regarding compliance to these requirements, please contact:	1
	For Rules Interpretation, call (703) 308-4216	

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200 To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED

JAN 2 1 2003

TECH CENTER 1600/2900